Compare Stocks: KMDA, BCAX, MAZE, and VIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$24.28 +2.8%	$26.15	$10.30 ▼ $30.99	$1.56B	-0.75	641,151 shs	479,906 shs
KMDA Kamada	$7.58 +4.4%	$7.22	$6.50 ▼ $9.35	$417.49M	0.86	71,344 shs	244,404 shs
MAZE Maze Therapeutics	$27.18 -1.8%	$27.79	$12.81 ▼ $53.65	$1.54B	2.21	352,009 shs	230,651 shs
VIR Vir Biotechnology	$9.24 +2.7%	$9.31	$4.25 ▼ $11.66	$1.52B	1.66	1.52 million shs	1.02 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-4.06%	-14.10%	-15.91%	+16.81%	+108.56%
KMDA Kamada	+5.52%	+1.68%	-0.14%	-5.84%	-1.63%
MAZE Maze Therapeutics	+0.51%	-3.01%	-7.40%	+8.26%	+103.46%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$24.28 +2.8%	$26.15	$10.30 ▼ $30.99	$1.56B	-0.75	641,151 shs	479,906 shs
KMDA Kamada	$7.58 +4.4%	$7.22	$6.50 ▼ $9.35	$417.49M	0.86	71,344 shs	244,404 shs
MAZE Maze Therapeutics	$27.18 -1.8%	$27.79	$12.81 ▼ $53.65	$1.54B	2.21	352,009 shs	230,651 shs
VIR Vir Biotechnology	$9.24 +2.7%	$9.31	$4.25 ▼ $11.66	$1.52B	1.66	1.52 million shs	1.02 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-4.06%	-14.10%	-15.91%	+16.81%	+108.56%
KMDA Kamada	+5.52%	+1.68%	-0.14%	-5.84%	-1.63%
MAZE Maze Therapeutics	+0.51%	-3.01%	-7.40%	+8.26%	+103.46%
VIR Vir Biotechnology	+0.45%	+2.62%	-5.16%	+2.39%	+96.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	2.73	Moderate Buy	$32.73	34.79% Upside
KMDA Kamada	3.00	Buy	$13.00	71.50% Upside
MAZE Maze Therapeutics	3.00	Buy	$66.00	142.83% Upside
VIR Vir Biotechnology	2.89	Moderate Buy	$20.63	123.21% Upside

Current Analyst Ratings Breakdown

Latest KMDA, BCAX, MAZE, and VIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $33.00
8/12/2026	BCAX Bicara Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/12/2026	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$16.00 ➝ $23.00
8/12/2026	BCAX Bicara Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $39.00
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/11/2026	BCAX Bicara Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $39.00
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	VIR Vir Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	$7.08 per share	N/A
KMDA Kamada	$180.46M	2.42	$0.64 per share	11.89	$4.69 per share	1.62
MAZE Maze Therapeutics	$167.50M	9.01	N/A	N/A	$8.16 per share	3.33
VIR Vir Biotechnology	$68.56M	22.81	N/A	N/A	$5.81 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	-$137.95M	-$2.78	N/A	N/A	N/A	N/A	-41.49%	-38.59%	N/A
KMDA Kamada	$20.20M	$0.35	19.95	12.23	0.64	11.60%	8.37%	5.85%	N/A
MAZE Maze Therapeutics	-$131.12M	-$2.53	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	N/A

Latest KMDA, BCAX, MAZE, and VIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	BCAX Bicara Therapeutics	-$0.8198	-$0.82	-$0.0002	-$0.82	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
5/14/2026	Q1 2026	KMDA Kamada	$0.12	$0.07	-$0.05	$0.07	$46.72 million	$45.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.19	2.51%	N/A	54.29%	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	11.59	13.85
KMDA Kamada	N/A	4.06	1.90
MAZE Maze Therapeutics	0.09	18.31	17.88
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
KMDA Kamada	20.38%
MAZE Maze Therapeutics	N/A
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	13.80%
KMDA Kamada	36.10%
MAZE Maze Therapeutics	5.30%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	66.17 million	57.04 million	N/A
KMDA Kamada	360	57.51 million	36.75 million	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
VIR Vir Biotechnology	580	169.22 million	164.31 million	Optionable

KMDA, BCAX, MAZE, and VIR Headlines

Recent News About These Companies

Q3 EPS Estimate for Vir Biotechnology Reduced by Analyst

August 14 at 1:28 AM | americanbankingnews.com

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

August 12 at 7:59 PM | finance.yahoo.com

Equities Analysts Offer Predictions for VIR Q3 Earnings

August 12 at 6:11 AM | marketbeat.com

Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities

August 12 at 3:58 AM | theglobeandmail.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 11 at 4:13 AM | marketbeat.com

Evercore ISI Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2026 | theglobeandmail.com

Vir Biotechnology (NASDAQ:VIR) Upgraded by Wall Street Zen to Hold Rating

August 8, 2026 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary

August 7, 2026 | finance.yahoo.com

Vir outlines ECLIPSE 1 top-line in Q4 2026 while projecting cash runway into the second half of 2028

August 6, 2026 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Vir Biotechnology Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

August 5, 2026 | zacks.com

Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates

August 5, 2026 | quiverquant.comQ

Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

August 5, 2026 | marketbeat.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 5, 2026 | businesswire.com

Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR

August 5, 2026 | marketbeat.com

Public Employees Retirement System of Ohio Acquires Shares of 112,700 Vir Biotechnology, Inc. $VIR

August 4, 2026 | marketbeat.com

950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP

August 1, 2026 | marketbeat.com

Vir Biotechnology (VIR) Expected to Post Earnings on Wednesday

July 29, 2026 | marketbeat.com

SB Investment Advisers UK Ltd. Sells 2,168,884 Shares of Vir Biotechnology, Inc. $VIR

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, BCAX, MAZE, and VIR Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$24.28 +0.65 (+2.75%)

Closing price 04:00 PM Eastern

Extended Trading

$24.28 0.00 (0.00%)

As of 07:34 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Kamada NASDAQ:KMDA

$7.58 +0.32 (+4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$7.58 0.00 (0.00%)

As of 07:34 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Maze Therapeutics NASDAQ:MAZE

$27.18 -0.49 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$27.21 +0.03 (+0.11%)

As of 07:34 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Vir Biotechnology NASDAQ:VIR

$9.24 +0.24 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$9.24 -0.01 (-0.05%)

As of 07:38 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, BCAX, MAZE, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, BCAX, MAZE, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, BCAX, MAZE, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, BCAX, MAZE, and VIR Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Kamada NASDAQ:KMDA

Maze Therapeutics NASDAQ:MAZE

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, BCAX, MAZE, and VIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, BCAX, MAZE, and VIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, BCAX, MAZE, and VIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

KMDA, BCAX, MAZE, and VIR Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

Kamada NASDAQ:KMDA

Maze Therapeutics NASDAQ:MAZE

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools